Alligator Bioscience AB ATORX

The issue constitutes part of the renegotiation of the outstanding loan from Fenja Capital which was raised in June 2024 and that the parties agreed on in connection with the rights issue of units resolved upon by the board of directors on 23 July 2026 (the "Rights Issue"). The Company can also announce that none of the guarantors who have entered into guarantee commitments in the Rights Issue have chosen to receive guarantee compensation in the form of newly issued units, which means that guara

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.LUND, SE / ACCESS Newswire / September 21, 2026 / (STO:ATORX) - The Board of Directors of AB ("" or the "Company"), today announces the prelimina

Alligator Bioscience AB (STU:7AL0) navigates a pivotal quarter, securing funding for its HLX22 royalty stream while winding down mitazalimab development.

LUND, SE / ACCESS Newswire / August 26, 2026 / Alligator Bioscience (STO:ATORX) - Today, on 26 August 2026, an extraordinary general meeting was held in Alligator Bioscience AB. The meeting resolved to amend § 4 of the Articles of Association so that the limits for the share capital in the company are changed. The meeting further resolved to decrease the company's share capital with SEK 112,379,938.92 to cover loss and without the redemption of shares.

LUND, SE / ACCESS Newswire / August 20, 2026 / Alligator Bioscience (STO:ATORX), a biotechnology company whose principal asset is a financial interest in the HER2-targeting antibody programme HLX22, will publish its interim report for April - June ...

LUND, SE / ACCESS Newswire / July 23, 2026 / Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders ...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX) First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral nivolumab Study evaluates how local CD40 activation ...

LUND, SE / ACCESS Newswire / June 8, 2026 / Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed by Shanghai Henlius Biotech, Inc. According to communication ...

LUND, SE / ACCESS Newswire / May 6, 2026 / Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, on ...

Mitazalimab momentum: Final OPTIMIZE‑1 outcomes were presented at ASCO GI 2026, with additional investigator‑initiated data accepted for AACR 2026. External portfolio progress: The first patient was dosed in Henlius’ Phase 2/3 study of HLX22 ...

LUND, SE / ACCESS Newswire / April 10, 2026 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab. ...